BRPI0514682A - composição de liberação rápida incluindo gránulos de derretimento de um medicamento sensìvel à umidade e processos para manufatura deste - Google Patents

composição de liberação rápida incluindo gránulos de derretimento de um medicamento sensìvel à umidade e processos para manufatura deste

Info

Publication number
BRPI0514682A
BRPI0514682A BRPI0514682-8A BRPI0514682A BRPI0514682A BR PI0514682 A BRPI0514682 A BR PI0514682A BR PI0514682 A BRPI0514682 A BR PI0514682A BR PI0514682 A BRPI0514682 A BR PI0514682A
Authority
BR
Brazil
Prior art keywords
moisture sensitive
composition including
release composition
processes
including melt
Prior art date
Application number
BRPI0514682-8A
Other languages
English (en)
Inventor
James Kowalski
Oskar Kalb
Abu T M Serajuddin
Yatindra Joshi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514682(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0514682A publication Critical patent/BRPI0514682A/pt
Publication of BRPI0514682B1 publication Critical patent/BRPI0514682B1/pt
Publication of BRPI0514682B8 publication Critical patent/BRPI0514682B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçãO DE LIBERAçãO RáPIDA INCLUINDO GRáNULOS DE DERRETIMENTO DE UM MEDICAMENTO SENSìVEL à UMIDADE E PROCESSOS PARA MANUFATURA DESTE Formas de dosagem oral sólidas que incluem grânulos de derretimento de um composto terapêutico sensível á umidade e um componente de derretimento hidrofóbico. Os grânulos de derretimento protegem melhor o composto terapêutico de degradação hidrolítica. Tais formas de dosagem oral sólidas também possuem características de liberação imediata ao invés de aquela associada com produtos de medicamentos de liberação extensa ou liberação controlada.
BRPI0514682A 2004-08-27 2005-08-26 processo para fabricar grânulos de composto terapêutico sensível à umidade e inibidor de dpp-iv, bem como composição farmacêutica de liberação imediata para administração oral compreendendo grânulos assim obtidos BRPI0514682B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60532704P 2004-08-27 2004-08-27
US60/605,327 2004-08-27
US61682804P 2004-10-07 2004-10-07
US60/616,828 2004-10-07
PCT/EP2005/009252 WO2006021455A1 (en) 2004-08-27 2005-08-26 Fast release composition including melt granules of a moisture sensitive drug and process for manufacturing thereof

Publications (3)

Publication Number Publication Date
BRPI0514682A true BRPI0514682A (pt) 2008-06-17
BRPI0514682B1 BRPI0514682B1 (pt) 2019-06-04
BRPI0514682B8 BRPI0514682B8 (pt) 2021-05-25

Family

ID=35447883

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514682A BRPI0514682B8 (pt) 2004-08-27 2005-08-26 processo para fabricar grânulos de composto terapêutico sensível à umidade e inibidor de dpp-iv, bem como composição farmacêutica de liberação imediata para administração oral compreendendo grânulos assim obtidos

Country Status (21)

Country Link
US (1) US20080050443A1 (pt)
EP (2) EP3087975A1 (pt)
JP (1) JP5147399B2 (pt)
KR (8) KR101613775B1 (pt)
CN (1) CN101010068B (pt)
AR (1) AR050615A1 (pt)
AU (1) AU2005276583B2 (pt)
BR (1) BRPI0514682B8 (pt)
CA (1) CA2575499A1 (pt)
DK (1) DK1786401T3 (pt)
ES (1) ES2647671T3 (pt)
HU (1) HUE034653T2 (pt)
MX (1) MX2007002253A (pt)
MY (1) MY144297A (pt)
PE (1) PE20060652A1 (pt)
PL (1) PL1786401T3 (pt)
PT (1) PT1786401T (pt)
RU (1) RU2383332C2 (pt)
SI (1) SI1786401T1 (pt)
TW (1) TWI402082B (pt)
WO (1) WO2006021455A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2684325T5 (es) 2004-01-20 2024-06-10 Novartis Ag Formulación y proceso de compresión directa
CA2554493C (en) 2004-02-05 2012-06-26 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
PE20060652A1 (es) 2004-08-27 2006-08-11 Novartis Ag Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion
JP5101489B2 (ja) 2006-03-08 2012-12-19 杏林製薬株式会社 アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体
WO2007128801A1 (en) * 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
ATE550319T1 (de) 2007-03-22 2012-04-15 Kyorin Seiyaku Kk Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats
DE102008020701A1 (de) * 2008-04-24 2009-10-29 Bayer Technology Services Gmbh Formulierung mit reduzierter Hygroskopizität
CA2732984A1 (en) 2008-08-07 2010-02-11 Kyorin Pharmaceutical Co., Ltd. Process for production of bicyclo[2.2.2]octylamine derivative
KR20110044780A (ko) * 2008-08-14 2011-04-29 교린 세이야꾸 가부시키 가이샤 안정화된 의약 조성물
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
CN102438617A (zh) 2009-03-27 2012-05-02 杏林制药株式会社 含有碱性添加剂的基质型缓释制剂
JP2011057586A (ja) * 2009-09-08 2011-03-24 Kyorin Pharmaceutical Co Ltd ｐＨ非依存性マトリックス型徐放性製剤
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
US8989577B2 (en) 2012-06-21 2015-03-24 Qualcomm Incorporated Methods and systems for implementing time-division duplexing in the physical layer
US9071358B2 (en) 2012-06-21 2015-06-30 Qualcomm Incrorporated Repeater fiber-coax units
US9363017B2 (en) 2012-07-06 2016-06-07 Qualcomm Incorporated Methods and systems of specifying coaxial resource allocation across a MAC/PHY interface
JP6283316B2 (ja) * 2012-10-26 2018-02-21 株式会社三和化学研究所 アナグリプチン含有固形製剤
US10369108B2 (en) * 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CN104274408A (zh) * 2013-07-10 2015-01-14 北京科信必成医药科技发展有限公司 一种熔融包衣的速释药物微粒及其制备方法
WO2015195990A1 (en) * 2014-06-20 2015-12-23 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
ES2946233T3 (es) 2016-09-16 2023-07-14 Galenicum Health S L U Composiciones farmacéuticas de vildagliptina

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
DK0654263T3 (da) 1993-11-23 2002-04-29 Euro Celtique Sa Fremgangsmåde til fremstilling af et præparat med langvarig frigivelse
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US20020142037A1 (en) * 1996-10-01 2002-10-03 Nabil Farah Process for the manufacture of a pharmaceutical composition with modified release of active principle comprising a matrix
AU4721897A (en) 1996-10-25 1998-05-22 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
JP2002522354A (ja) * 1997-09-19 2002-07-23 シャイア ラボラトリーズ，インコーポレイテッド 固溶体ビードレット
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
MXPA03006918A (es) 2001-02-02 2004-05-24 Takeda Chemical Industries Ltd Compuestos heterociclicos fusionados.
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
EP1537880A4 (en) * 2002-09-11 2009-07-01 Takeda Pharmaceutical PREPARATION FOR PROLONGED RELEASE
WO2004037169A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1553937B1 (en) 2002-10-23 2010-06-02 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv
PE20060652A1 (es) 2004-08-27 2006-08-11 Novartis Ag Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion

Also Published As

Publication number Publication date
HUE034653T2 (hu) 2018-02-28
EP3087975A1 (en) 2016-11-02
AU2005276583A1 (en) 2006-03-02
KR20190006612A (ko) 2019-01-18
KR20160136465A (ko) 2016-11-29
KR20160017123A (ko) 2016-02-15
CA2575499A1 (en) 2006-03-02
MX2007002253A (es) 2007-04-20
PL1786401T3 (pl) 2018-01-31
KR20130043697A (ko) 2013-04-30
JP2008510764A (ja) 2008-04-10
AR050615A1 (es) 2006-11-08
EP1786401A1 (en) 2007-05-23
KR20200087870A (ko) 2020-07-21
EP1786401B1 (en) 2017-08-16
ES2647671T3 (es) 2017-12-26
AU2005276583B2 (en) 2009-12-03
RU2007110953A (ru) 2008-10-10
TW200613005A (en) 2006-05-01
MY144297A (en) 2011-08-29
US20080050443A1 (en) 2008-02-28
KR101613775B1 (ko) 2016-04-19
RU2383332C2 (ru) 2010-03-10
CN101010068B (zh) 2013-05-22
TWI402082B (zh) 2013-07-21
KR20070049646A (ko) 2007-05-11
CN101010068A (zh) 2007-08-01
KR20170103039A (ko) 2017-09-12
PT1786401T (pt) 2017-11-22
BRPI0514682B1 (pt) 2019-06-04
DK1786401T3 (da) 2017-11-27
WO2006021455A1 (en) 2006-03-02
SI1786401T1 (sl) 2017-12-29
KR20220061249A (ko) 2022-05-12
BRPI0514682B8 (pt) 2021-05-25
PE20060652A1 (es) 2006-08-11
JP5147399B2 (ja) 2013-02-20

Similar Documents

Publication Publication Date Title
BRPI0514682A (pt) composição de liberação rápida incluindo gránulos de derretimento de um medicamento sensìvel à umidade e processos para manufatura deste
DK1957110T3 (da) Fremgangsmåde til fremstilling af tygbare doseringsformer til lægemiddeladministration og produkter dermed
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
WO2007081948A3 (en) Bioadhesive drug formulations for oral transmucosal delivery
HK1118019A1 (zh) 用於治療癌症的包含ω-羧芳基取代的二苯基脲的藥物組合物
BRPI0606145C1 (pt) formas farmacêuticas sólidas de cloridrato de oxicodona resistentes ao rompimento com liberação sustentada
CL2007002974A1 (es) Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
BRPI0819864A2 (pt) composição farmacêutica destinada ao tratamento de doenças relacionadas à obesidade que compreende um conjugado peptídico insulinotrópico
LTC1765293I2 (lt) Farmacinės kompozicijos vaistų pristatymui ir būklių gydymo arba prevencijos būdai naudojant tas kompozicijas
BRPI0619153B8 (pt) derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica
WO2009074300A8 (en) Hedgehog pathway antagonists and therapeutic applications thereof
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
BRPI0820868A2 (pt) composto de tiofeno fórmula(i), composição farmacêutica contendo o mesmo e uso deste para a prevenção ou tratamento de doenças ou disturbíos associados a um sistema imune ativado
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
WO2007053641A3 (en) A-type procyanidins and inflammation
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
BRPI0209720A2 (pt) dosagem e embalagem de medicação com liberação controlada
SE0303571D0 (sv) Medical product for moisture-sensitive medicaments
WO2009111611A3 (en) Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
CY1114311T1 (el) Θεραπευτικα συστηματα αμεσης απελευθερωσης για βελτιωμενη απο του στοματος απορροφηση 7-[(ε)-τριτ-βουτυλοξυιμινομεθυλο]καμπτοθεκινης
EA200970529A1 (ru) Антивирусная композиция и способ ее применения
BRPI0518790A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF